---
title: The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant
  glioma
date: '2024-12-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39723472/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241226170935&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant
  primary brain tumors in young adults. This condition imposes a substantial burden
  on patients and their caregivers, marked by neurocognitive deficits and high mortality
  rates due to tumor progression, coupled with significant morbidity from current
  treatment modalities. Although surgery, radiation therapy, and chemotherapy improve
  survival, these treatments can adversely affect cognitive function, quality of ...
disable_comments: true
---
Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of ...